2. Apoptosis Anti-infection
  3. Apoptosis SARS-CoV
  4. Corisin

Corisin is a pro-apoptotic small peptide produced by Staphylococcus species. Corisin binds to serum albumin to target organs such as the lungs and kidneys, induces cellular senescence, apoptosis and epithelial-mesenchymal transition, and accelerates the progression of organ fibrosis including pulmonary fibrosis and diabetic renal fibrosis. Corisin levels are closely associated with coronavirus disease 2019 (COVID-19), diabetic chronic kidney disease (CKD), non-diabetic CKD, and idiopathic pulmonary fibrosis (IPF).

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Corisin

Corisin Chemical Structure

CAS No. : 2651277-02-8

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Corisin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Corisin is a pro-apoptotic small peptide produced by Staphylococcus species. Corisin binds to serum albumin to target organs such as the lungs and kidneys, induces cellular senescence, apoptosis and epithelial-mesenchymal transition, and accelerates the progression of organ fibrosis including pulmonary fibrosis and diabetic renal fibrosis. Corisin levels are closely associated with coronavirus disease 2019 (COVID-19), diabetic chronic kidney disease (CKD), non-diabetic CKD, and idiopathic pulmonary fibrosis (IPF)[1][2][3].

In Vitro

Corisin (48 h) significantly increases phosphatidylserine externalization in human umbilical vein endothelial cells, and this effect is blocked by anti-Corisin monoclonal antibodies[1].
Corisin (5 μM; 24 h) significantly enhances tissue factor activity in A549 alveolar epithelial cells, THP-1 monocytes and human umbilical vein endothelial cells, and this effect is reversed by anti-Corisin monoclonal antibody or anti-TF antibody[1].
Corisin (5 μM; 24 h) significantly reduces thrombomodulin activity in A549 alveolar epithelial cells, THP-1 monocytes and human umbilical vein endothelial cells, and this effect is reversed by anti-Corisin monoclonal antibodies[1].
Corisin (20-40 μg/mL; 24-48 h) promotes apoptosis, disrupts cell cycle progression and reduces proliferative activity in normal human renal proximal tubular epithelial cells, human Caki-2 renal tubular epithelial cells and normal human podocytes, while anti-Corisin monoclonal antibodies inhibit these effects[2].
Corisin (20-40 μg/mL; 48 h) induces cellular senescence in human Caki-2 renal tubular epithelial cells, normal human primary renal tubular epithelial cells, and normal human primary podocytes, which is characterized by increased senescence-associated β-galactosidase activity, altered expression of senescence marker genes, and abnormal nuclear morphology. This effect is inhibited by anti-Corisin monoclonal antibodies[2].
Corisin (20-40 μg/mL; 48 h) induces epithelial-mesenchymal transition in human normal primary podocytes and human normal primary renal proximal tubular epithelial cells, which is characterized by changes in cell morphology and upregulated expression of mesenchymal marker genes, while anti-corisin monoclonal antibodies inhibit these effects[2].
Stimulation of primary human renal proximal tubular epithelial cells with Corisin (20 μg/mL; 24 h) activates pathways associated with DNA damage response, cellular senescence, senescence-associated secretory phenotype, and myofibroblast-like differentiation[2].
Corisin (0.5-50 μM; 16-48 h) induces dose-dependent apoptosis in A549 alveolar epithelial cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Corisin Related Antibodies

Apoptosis Analysis[3]

Cell Line: A549 alveolar epithelial cells
Concentration: 0.5 μM, 5 μM, 50 μM (48 h); 5 μM (16 h)
Incubation Time: 48 h (0.5 μM, 5 μM, 50 μM); 16 h (5 μM)
Result: Induced apoptosis in a dose-dependent manner.
Increased Annexin V-positive cells to 13.7% at 0.5 μM, 21.1% at 5 μM, and 22.7% at 50 μM, all significantly higher than the control 6.2%.
Confirmed apoptotic morphology via transmission electron microscopy at 5 μM.
In Vivo

Corisin (5 mg/kg; i.p.; three times per week for 2 weeks) significantly exacerbates renal fibrosis and renal function injury in TGFβ1 transgenic mice by promoting inflammatory responses and fibrotic changes[2].
Corisin (administered intratracheally; once daily for 2 consecutive days) induces acute exacerbation of pulmonary fibrosis in TGFβ1 TG mice, which is characterized by significant increases in pulmonary inflammation, collagen deposition, levels of profibrotic mediators, and epithelial cell apoptosis[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: TGFβ1 transgenic (female, 9 weeks old)[2]
Dosage: 5 mg/kg
Administration: i.p.; thrice weekly; 2 weeks
Result: Elevated urinary levels of corisin, albumin, and albumin-to-creatinine ratio significantly compared to scrambled peptide-treated mice.
Elevated plasma blood urea nitrogen (BUN) and urinary liver-type fatty acid-binding protein (L-FABP) levels significantly compared to scrambled peptide-treated mice.
Elevated plasma levels of lipopolysaccharide-induced CXC chemokine (LIX/CXCL5), macrophage inflammatory protein-2 (MIP-2), interleukin-1β (IL-1β), platelet-derived growth factor (PDGF), tissue factor (TF), and plasminogen activator inhibitor-1 (PAI-1) significantly compared to scrambled peptide-treated mice.
Increased mean circulating corisin levels to 2.2-fold higher than those in diabetic CKD patients and 1.6-fold higher than those in diabetic TGFβ1 transgenic mice.
Increased renal fibrotic changes significantly compared to scrambled peptide-treated mice.
Molecular Weight

1973.17

Formula

C84H133N25O28S
CAS No.
Appearance

Solid

Color

White to off-white

Sequence

Ile-Val-Met-Pro-Glu-Ser-Ser-Gly-Asn-Pro-Asn-Ala-Val-Asn-Pro-Ala-Gly-Tyr-Arg
Sequence Shortening

IVMPESSGNPNAVNPAGYR
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 25 mg/mL (12.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.5068 mL 2.5340 mL 5.0680 mL
5 mM 0.1014 mL 0.5068 mL 1.0136 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (1.27 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (1.27 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 0.5068 mL 2.5340 mL 5.0680 mL 12.6700 mL
5 mM 0.1014 mL 0.5068 mL 1.0136 mL 2.5340 mL
10 mM 0.0507 mL 0.2534 mL 0.5068 mL 1.2670 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Corisin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Corisin2651277-02-8ApoptosisSARS-CoVSARS coronavirusmonocytic cellsalveolar epithelial cellsStaphylococcus specieskidney podocyteCOVID-19endothelial cellsrenal tubular epithelial cellsidiopathic pulmonary fibrosisnon-diabetic CKDdiabetic chronic kidney diseaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Corisin
Cat. No.:
HY-P11178
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.